Tune Therapeutics
Durham, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $175M
Overview
A pioneer in epigenetic editing, using CRISPR to tune gene expression without DNA breaks for durable therapeutics.
OncologyGenetic Diseases
Technology Platform
The TEMPO platform uses CRISPR-guided systems to write programmable epigenetic marks, enabling precise activation or silencing of genes without making double-strand breaks in DNA.
Funding History
1Total raised:$175M
Series B$175M
Opportunities
To create a new therapeutic modality that controls gene expression networks for complex diseases untreatable by current genetic medicines.
Risk Factors
Technology is early-stage with unproven in vivo efficacy, durability, and safety profile compared to established modalities.
Competitive Landscape
Competes with other epigenetic editing startups like Chroma Medicine in a nascent but rapidly evolving field beyond traditional CRISPR-Cas9.